The American Association for the Study of Liver Diseases, in collaboration with the American College of Gastroenterology and American Gastroenterological Association, have developed new guidelines for the diagnosis and management of Nonalcoholic Fatty Liver Disease (NAFLD). The practice guideline was co-published in the June 2012 issues of the official journals of the sponsoring societies.
The guideline is intended for physicians and allied health professionals and provides recommendations that suggest preferred approaches to the diagnosis, therapeutic and preventive aspects of care. While obesity is a risk factor for NAFLD, there is a very high prevalence in individuals with type 2 diabetes mellitus and progression to advanced fibrosis and mortality increases in older patients. The recommendations address NAFLD in children and adults.
Download this timely and free practice guideline.
A Few Topics;
Screening of Family Members
Non-invasive assessment of steatohepatitis and advanced fibrosis in NAFLD
Ursodeoxycholic acid (UDCA), Omega-3 fatty acids, and Miscellaneous Agents
Alcohol use in patients with NAFLD and NASH
Statin use in patients with NAFLD and NASH
NAFLD in patients with other chronic liver diseases
Aspects of NAFLD Specific to Children and Adolescents
- Newly Diagnosed
- All FDA Approved Drugs To Treat Hepatitis C
- 2017-HCV Genotypes/Treatment
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Not FDA Approved - Sofosbuvir/Velpatasvir/Voxilaprevir
- Not FDA Approved - Glecaprevir/Pibrentasvir (G/P)
- NOT FDA Approved - MK3 (MK-3682/grazoprevir/ruzasvir1)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- FibroScan® Understanding The Results
- Is There A Natural Way To Improve Liver Fibrosis?
- Staging Cirrhosis